Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22989589 | 0.83 | CYP1A2 (0.30) | CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL11762546 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP2D6HSD17B10CYP2C9HPGD | |
| SCHEMBL28891324 | 0.75 | MAPT (0.35) | — | |
| SCHEMBL19781528 | 0.74 | CYP1A2 (0.41) | CYP1A2CYP2D6HSD17B10CYP2C9HPGD | |
| SCHEMBL19768951 | 0.71 | CYP1A2 (0.39) | CYP1A2CYP2D6HSD17B10CYP2C9HPGD | |
| SCHEMBL26420702 | 0.71 | CYP1A2 (0.39) | CYP1A2CYP2D6HSD17B10CYP2C9HPGD | |
| SCHEMBL28214150 | 0.70 | KMT2A (0.30) | — | |
| Diethylaminoethanol SCHEMBL10699915 | 0.69 | — | — | |
| Diethylaminoethanol SCHEMBL3114 | 0.69 | — | — | |
| SCHEMBL35602 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938249-B2 | Anti-amyloid compounds containing benzofurazan | TREVENTIS CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORPORATION (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | PRNP, PSEN1, APP | CYP1A2 1950/4885CYP2D6 2985/4885HSD17B10 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.